4517 related articles for article (PubMed ID: 7914469)
21. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
22. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma.
Facchetti P; Prigione I; Ghiotto F; Tasso P; Garaventa A; Pistoia V
Cancer Immunol Immunother; 1996 Mar; 42(3):170-8. PubMed ID: 8640845
[TBL] [Abstract][Full Text] [Related]
23. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
24. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
25. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
[TBL] [Abstract][Full Text] [Related]
26. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.
Pandolfino MC; Viret C; Gervois N; Guilloux Y; Davodeau F; Diez E; Jotereau F
Eur J Immunol; 1992 Jul; 22(7):1795-802. PubMed ID: 1623924
[TBL] [Abstract][Full Text] [Related]
27. Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.
Baxevanis CN; Dedoussis GV; Gritzapis AD; Stathopoulos GP; Papamichail M
Br J Cancer; 1994 Oct; 70(4):625-30. PubMed ID: 7917907
[TBL] [Abstract][Full Text] [Related]
28. Autologous tumour-specific cytotoxic T-cell clone established from tumour-infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2(rIL2): activation by autologous tumour cell alone.
Katano M; Nagumo F; Kubota E; Yamamoto H; Matsuo T; Hisatsugu T; Tadano J
Biotherapy; 1993; 6(1):25-32. PubMed ID: 8507542
[TBL] [Abstract][Full Text] [Related]
29. In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.
Apiranthitou-Drogari M; Paganin C; Bernasconi S; Losa G; Maneo A; Colombo N; Mantovani A; Allavena P
Cancer Immunol Immunother; 1992; 35(4):289-95. PubMed ID: 1387344
[TBL] [Abstract][Full Text] [Related]
30. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma.
Koo AS; Tso CL; Shimabukuro T; Peyret C; deKernion JB; Belldegrun A
J Immunother (1991); 1991 Oct; 10(5):347-54. PubMed ID: 1790142
[TBL] [Abstract][Full Text] [Related]
31. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
[TBL] [Abstract][Full Text] [Related]
32. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
[TBL] [Abstract][Full Text] [Related]
33. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
[TBL] [Abstract][Full Text] [Related]
34. [Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2].
Itoh K; Shiiba K; Ebina N; Anzai R; Ouchi A; Matsuno S
Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):781-90. PubMed ID: 8377752
[TBL] [Abstract][Full Text] [Related]
35. Peripheral blood and tumor infiltrating lymphocytes in non-small cell lung cancer: analysis at the population and clonal level.
Viale M; Ferrini S; Serrano S; Serrano D; Ardizzoni A; Nicolin A
Tumori; 1990 Oct; 76(5):488-94. PubMed ID: 2175060
[TBL] [Abstract][Full Text] [Related]
36. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
37. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma.
Hilders CG; Ras L; van Eendenburg JD; Nooyen Y; Fleuren GJ
Int J Cancer; 1994 Jun; 57(6):805-13. PubMed ID: 8206676
[TBL] [Abstract][Full Text] [Related]
38. A correlation between the expression of CD 8 antigen and specific cytotoxicity of tumor-infiltrating lymphocytes.
Okada Y; Yahata G; Takeuchi S; Seidoh T; Tanaka K
Jpn J Cancer Res; 1989 Mar; 80(3):249-56. PubMed ID: 2524461
[TBL] [Abstract][Full Text] [Related]
39. T cell receptor gene rearrangements and cytotoxic activities of clones isolated from tumour-infiltrating lymphocytes (TIL) from melanoma patients.
Pandolfi F; Boyle LA; Trentin L; Oliva A; Kurnick JT
Clin Exp Immunol; 1994 Jan; 95(1):141-7. PubMed ID: 8287599
[TBL] [Abstract][Full Text] [Related]
40. Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype.
Patel SS; Thiele DL; Lipsky PE
J Immunol; 1987 Dec; 139(11):3886-95. PubMed ID: 3500232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
